To view the PDF file, sign up for a MySharenet subscription.

CIPLA MEDPRO SOUTH AFRICA LIMITED - Changes to the Board of directors

Release Date: 26/11/2012 09:00
Code(s): CMP     PDF:  
Wrap Text
Changes to the Board of directors

Cipla Medpro South Africa Limited
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
Share code: CMP
ISIN: ZAE000128179
(“Cipla Medpro” or the "Company")


Changes to the Board of directors

Shareholders are informed that Mr Chris Aucamp has resigned as Chief Financial Officer and
executive director of Cipla Medpro with immediate effect. Mr Aucamp has agreed to remain in the
employment of the subsidiary Medpro Pharmaceutica Proprietary Limited, where he will remain as a
director, until at least 31 March 2013. Mr Aucamp will provide assistance to Cipla Medpro, as
required, with regard to the finalisation of the 2012 year-end audit and annual financial statements
as well as a hand over to the new Chief Financial Officer.

Shareholders are further notified that Mr Mark Daly has been appointed as the Chief Financial
Officer of Cipla Medpro and as an executive director of the Company with effect from 26 November
2012. Mr Daly is a chartered accountant and holds a B.Com Honours degree in accounting from the
University of Natal Pietermaritzburg. He currently serves as Company Secretary for Cipla Medpro
and Financial Director of the manufacturing division in Durban. Mr Daly has been with the Cipla
Medpro group for almost 6 years and prior to that he was a manager in the Corporate Finance and
Auditing departments at KPMG.

The appointment of a new company secretary will be announced in due course.

Durban
26 November 2012

Sponsor
Nedbank Capital

Date: 26/11/2012 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story